RE:RE:Price upgrade I don’t know of this article you speak of or if it exists but I can assure you without a doubt, if any analyst from the Globe And Mail wrote any article or for that matter ANY analyst worth a grain of salt wrote anything, it most surely would be easlily found. Moreover, to convey here that a non existent article with a non existent price grade is erroneous and a non existent retraction was forthcoming to “amend” the price forecast from $17.00 to $7.00 is beyond absurd since LABS has recently ALREADY topped the $7.00 so called amended target.
If there is such an article I would argue that a target of $17.00 as with most forecasts appears to be on the high side but not completely out of line with other forecasters or major banks as they tend have an overly elevated targets one way or another for most companies.
While $17.00 may seem overly optimistic over a period of 12 to 18 months, I would argue that it is NOT beyond the range of realism.
As for the upcoming earnings report on Monday, I don’t have a crystal ball, nor do I profess to be an analyst, but I have been trading for over ten years and I have seldom seen a company doubling their revenue from one quarter to the next and suddenly reverse course. When revenue doubles it can only mean good things are coming in subsequent earnings. WIll the revenue double again ? It would not surprise me in the least.
Ravenus01 wrote: It was an error on the part of Globe & Mail apparently:
TraderNickCFA
@nickchen66
33m33 minutes ago
More
$LABS $MEDIF followers: I'm told the Globe & Mail got the price target wrong. Should have been $7 not $17. Expect a retraction and ammendment tomorrow. This doesn't change our bull case for the stock. Although we won't get the easy lift we were expecting!